Having trouble accessing articles? Reset your cache.

Biogen turns to R&D vet as Ehlers exits

While Biogen head of R&D Michael Ehlers is departing the biotech to join the VC ranks amid a series of recent clinical disappointments, pipeline additions during his tenure could start to bear fruit over the next nine months.

Biogen Inc. (NASDAQ:BIIB) said Al Sandrock, who has been at the company since 1998

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers